HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
about
Uveal melanoma as a target for immune-therapyUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsImmune escape mechanisms as a guide for cancer immunotherapyImmunological battlefield in gastric cancer and role of immunotherapiesChemical metabolic inhibitors for the treatment of blood-borne cancersNovel insights into the molecular mechanisms of HLA class I abnormalities.Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responsesSusceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer.Immunotherapy as a Potential Treatment for Chordoma: a Review.Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients.Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaEpigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinomaPheophorbide a-Mediated Photodynamic Therapy Triggers HLA Class I-Restricted Antigen Presentation in Human Hepatocellular Carcinoma.HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.Strategies for cancer vaccine development.Clinical implication of HLA class I expression in breast cancerThe effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related moleculesHLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerReprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Integrating multidimensional omics data for cancer outcome.Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells.HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionMultiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.Innovative therapeutic strategies in the treatment of brain metastases.Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
P2860
Q26747519-9E519BB2-2774-4B5F-96D1-D3ECA66B7A66Q26751011-E0925D29-E9A8-47F3-AAEF-D7E99C8C59E3Q27024502-DF4EBCFF-1B30-45BB-815E-FF7D0F9C2103Q28071836-38AC1781-E0E8-41AC-8427-1EF633E7F118Q28822335-A6630835-ACEA-404F-84F0-58A5800A4601Q30318252-3F0DBBDB-425D-4F7C-812E-405B3DB330CCQ30318613-A192D903-93E9-4F1C-B253-0455F8DEA3F5Q30600094-E3C55A44-1454-47B2-9D6C-E8B36CEB9C8AQ30975364-7A27BCEF-F375-4EAB-9397-94F7ECD4DF1BQ31021595-22641B9A-C0AC-428A-9EAF-66B622A07D80Q33276143-65FC6BEF-B38F-40AA-A607-178AF2BD0F8CQ33391089-9056288E-47E7-40A9-954E-C4BF84AF190DQ33595804-77E576A3-EE51-4F83-9AEA-85E2F63B3A2EQ33677445-C8742D4E-523A-4D29-A05D-0253721B4B59Q33720183-2477BCAE-2EAC-4A74-995A-578E5E9A248CQ33760601-74FF39A5-44E8-4B4D-AB8B-0ACA59F2A9DBQ33849679-2CA13E3B-FBDD-4D9F-9311-AFF01C1056E5Q33855049-DE866D98-A025-49DD-A2E3-127398B60903Q33942994-72B3C71F-3291-4DED-8414-C29F6C33295BQ34038338-CBAFDB7D-14F0-4B0D-8091-13514E428202Q34052449-F94D6C80-F617-4311-AD91-AC0DE9FDCE8EQ34128134-6AAF2467-D911-478B-8867-8498125EC55FQ34985471-D075415C-2CC9-4297-B4EA-7497CB6B5D9CQ35328953-C6BB6906-4EAB-411A-B3E1-ACC08535558DQ35584599-918E8C91-3ACA-475B-8BC0-D63D2481DA93Q35762219-CCF54E98-827A-429E-9AA2-5067F3A336F3Q35786634-C5269D66-7912-4D07-8DBA-135A32D5EF5DQ35799094-252E1D1D-A031-4DE0-839F-5F5F6D731C46Q35931598-B62C9FBC-FD71-48A9-8C39-A856A51965B8Q35939427-270DBDF8-DEE0-4C1D-ACC8-840BCDEFDB37Q35958732-975B0781-2D84-4097-9611-2E956772F2DCQ36002622-F656C083-13A2-4EC9-89C0-C0225A764330Q36024656-CA45D771-E2CC-476C-BBF6-7060C720EBE8Q36184778-0B2FC408-CA3D-4054-8DAF-35AED626428FQ36184954-DA776068-2224-4B32-8A43-019DA5667D80Q36283696-735D5F1F-E391-4429-BB07-E6C3DDC962B8Q36590195-D3DE51B9-FBA8-4BC7-B3C5-2588F0B5A26EQ36750601-63EF54FF-0A49-4689-A419-DEA09D88E681Q36946516-218CD8DB-F2D2-4DBE-889D-F65F97D0593AQ36957315-A355DCD2-7FA8-4A41-AE09-9DE8DB7C6B34
P2860
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
@en
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
@nl
type
label
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
@en
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
@nl
prefLabel
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
@en
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
@nl
P2860
P356
P1433
P1476
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2008.273
P407
P577
2008-10-01T00:00:00Z